Online inquiry

IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13595MR)

This product GTTS-WQ13595MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13595MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5649MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ15430MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ13208MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ3011MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ6877MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ5775MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ9118MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ14920MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW